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131I) therapy is widely accepted as an essential part of therapeutic regimens in many
cases of differentiated thyroid cancer. Radiation-induced oxidative damage to macromolecules is a well known
phenomenon. Frequently examined process to evaluate oxidative damage to macromolecules is lipid peroxidation
(LPO), resulting from oxidative damage to membrane lipids. The aim of the study was to examine serum LPO level
in hypothyroid (after total thyroidectomy) cancer patients subjected to ablative activities of
131I.
Materials and methods: The study was carried out in 21 patients (18 females and 3 males, average age 52.4 ±
16.5 years) after total thyroidectomy for papillary (17 patients) or follicular (4 patients) thyroid carcinoma.
Hypothyroidism was confirmed by increased TSH blood concentration (BRAHMS, Germany), measured before
131I
therapy. Activity of 2.8 - 6.9 GBq of
131I was administered to the patients orally as sodium iodide (OBRI, Poland).
Concentrations of malondialdehyde + 4-hydroxyalkenals (MDA + 4-HDA), as an index of LPO (LPO-586 kit,
Calbiochem, USA), were measured in blood serum just before
131I administration (day “0”) and on the days 1-4
after
131I therapy. Sera from 23 euthyroid patients served as controls. Correlations between LPO and TSH or
131I
activity were calculated.
Results: Expectedly, serum LPO level, when measured before
131I therapy, was several times higher (p < 0.00001)
in cancer patients than in healthy subjects, which is probably due to hypothyroidism caused by total
thyroidectomy. However, we did not observe any differences between LPO levels after and before
131I therapy. LPO
did not correlate with TSH concentration. In turn, negative correlation was found between
131I activity and LPO
level on the day “2” after radioiodine treatment.
Conclusions: Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative
damage to membrane lipids, at least early, after therapy.
Introduction
Radioiodine (
131I )a d m i n i s t r a t i o ni saw i d e l ya c c e p t e d
method of therapy in both benign and malignant thyroid
disorders. However, besidesi t sd e s i r e de f f e c t so nt h e
thyroid tissue, ionizing radiation may cause cellular oxi-
dative damage both directly, by disruption of DNA
integrity, and indirectly, as a result of the formation of
intracellular free radicals [1]. When the free radicals are
generated closely to or within lipid membranes, they
can attack the fatty acid side-chains of the membrane
phospholipids and, then, lipid peroxidation (LPO) may
occur [2]. Such a phenomenon relates practically to all
cellular membranes of any tissue, and the products of
LPO are thereafter translocated into body fluids, blood
included.
Increased amounts of LPO end products can be, how-
ever, detected in many diseases, as an index of cell
destruction, because cells and tissues damaged by any
mechanism may peroxidize more rapidly than normal
ones [3]. For example, increased LPO level was found in
blood serum of critically ill patients, of adult growth
hormone deficient patients, or of newborns with respira-
tory distress syndrome or with sepsis, as well as in rat
blood serum after exposure to different carcinogens
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also described in blood serum of patients with hypothyr-
oidism [10-13].
Well documented is radiation-induced oxidative
damage to macromolecules [14]. Total body ionizing
irradiation increased liver DNA and membrane lipid
damage, as well as increased LPO level in blood serum
in rats [15]. Also human tissues were documented to be
sensitive to damaging effects of ionizing radiation. For
example, exposure of human blood leukocytes to exter-
nal irradiation increased DNA damage [16]. The hypoth-
esis on the radiation-related processes of aging, via the
mechanism of oxidative stress, is supported by many
scientists [17].
Radioiodine treatment for differentiated thyroid cancer
is associated with the application of, usually, high so
called ablative activities of
131I (1.85 - 7.4 GBq), produ-
cing ionizing radiation at comparatively high level,
resulting in significant radiation dose to the patient.
Thus, unfavourable effects of such a treatment, in terms
of oxidative damage to macromolecules, should be con-
sidered. It has been already documented, that oxidative
damage to membrane lipids increases after more than
5 days [18]. However, the early effects of
131Ii nt h y r o i d
cancer patients on oxidative damage to macromolecules
have never been examined.
Therefore, in the present study we examined the early
effects of ablative activities of
131I in thyroid cancer
patients on serum lipid peroxidation. The measurements
were performed only within the first four days after the
treatment, before levothyroxine replacement, to avoid
possible favourable effects of such a replacement.
Materials and methods
The study was carried out in 21 patients (18 females
and 3 males, average age 52.4 ± 16.5 years) 4 weeks
after total thyroidectomy for papillary (17 patients) and
follicular (4 patients) thyroid carcinoma. After overnight
fasting, blood samples were collected in the morning on
the day of
131I administration before therapy (day “0”)
and daily thereafter until the 4
th day.
TSH concentration (BRAHMS, Germany) was mea-
sured in a sample obtained before therapy and concen-
trations of malondialdehyde + 4-hydroxyalkenals (MDA
+ 4-HDA), as the index of LPO, were measured in the
blood serum by an LPO assay (LPO-586 kit, Calbio-
chem, USA) in all samples. Activity of 2.8 - 6.9 GBq of
131I was administered to the patients orally as sodium
iodide (OBRI, Poland).
Sera from a group of 23 euthyroid patients (confirmed
by normal thyroid hormone levels; fT3, fT4, TSH, all
BRAHMS, Germany), matched for sex and age, served
as controls.
LPO assay
After collection, blood was centrifuged (3000 × g,
10 min, 4°C) in order to obtain serum, and stored at
-80°C until assay. The concentrations of MDA and
4-HDA, as the index of LPO, were measured in blood
serum, using an LPO-586 kit. Briefly, serum (200 ml)
was mixed with 650 ml of a methanol:acetonitrile
(1:3, v/v) solution, containing a chromogenic reagent,
N-methyl-2-phenylindole, and vortexed. After adding
150 ml of methanesulfonic acid (15.4 M), incubation
was carried out at 45°C for 40 min. The reaction
between MDA + 4-HDA and N-methyl-2-phenylindole
yields a chromophore, which is spectrophotometrically
measured at the absorbance of 586 nm, using a solu-
tion of 4-hydroxynonenal (10 mM) as the standard.
The level of LPO was expressed as the amount of
M D A+4 - H D A( n m o l )p e r1m lo fs e r u m .
Statistical analysis
LPO in the study group on day “0” was compared with
that of the control group, and LPO’s in the study group
on days 1-4 were compared with baseline value (Mann-
Whitney U test and Wilcoxon’s matched pairs test,
respectively). Correlation between LPO and TSH, as well
as between LPO and
131I was calculated (Spearman test).
The study protocol was accepted by the Ethical Com-
mittee of the Medical University of Lodz and written,
informed consent was obtained from all patients.
Results
Results are shown in Table 1.
Expectedly, serum LPO level, when measured before
131I therapy, was several times higher (p < 0.00001) in
cancer patients than in healthy subjects. We did not,
however, observe any difference between LPO in
hypothyroid patients after and before
131It h e r a p y( d a y
“1” vs day “0”, p = 0.56; day “2” vs day “0”, p = 0.83; day
“3” vs day “0”, p = 0.65; day “4” vs day “0”, p = 0.80). No
correlation was found between TSH and LPO on day
“0” (rs = 0.22; p = 0.37). However, clear negative correla-
tion was found between administered activity of
131I and
LPO, when evaluated on day “2”, being already at bor-
derline level of statistical significance on day “1"; the
negative correlation disappeared on day “3” and on day
“4”. Data are summarized in Table 2.
Discussion
Lipid peroxidation is a well-established indicator of oxi-
dative stress in cells and tissues [19]. Lipid peroxides
are unstable and decompose to form a series of com-
pounds, including MDA and 4-HDA, and the measure-
ment of MDA + 4-HDA has been used as an indicator
of LPO [20,21].
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with the control group of patients with normal thyroid
function. Our results are similar to those reported by
Dumitriu et al., who found serum MDA level signifi-
cantly higher in hypothyroidism when compared with
the control group of euthyroid patients [10]. Further-
more, two independent groups described significant
reduction of increased serum MDA levels after treat-
ment of hypothyroidism with the use of levothyroxine
[11,12]. Also Konukoğlu et al. found that increased
LPO, when measured by thiobarbituric acid reactive
substance (TBARS) method, was significantly reduced
after treatment with levothyroxine [13]. The increased
LPO level observed in both overt and subclinical
hypothyroidism was recently explained by the insuffi-
cient increase in the antioxidant status, as well as by the
altered lipid metabolism [22].
T h em a i nf i n d i n go ft h ep r e s e n ts t u d yi st h a tw ed i d
not demonstrate any additive effect of ablative doses of
131I on serum LPO in hypothyroid patients. Our results
contrast with those reported by Konukoğlu et al.,w h o
observed higher MDA levels in erythrocyte membranes
2 days after treatment with
131I in patients after subtotal
thyroidectomy treated with 3.7 - 5.55 GBq
131I [23].
This apparent discordance may be explained by the high
radiation sensitivity of bone marrow producing erythro-
cytes, the phenomenon which does relate to the present
study. In turn, Wolfram et al. observed significant
increase in isoprostane level in compartments such as
blood plasma or serum and urine, shortly after radioio-
dine treatment in thyroid cancer patients [24]. As iso-
prostanes result from oxidation of low-density
lipoprotein present in blood, whereas MDA + 4-HDA,
evaluated in the present study, result from oxidative
damage to membrane lipids of different tissues and
organs, which thereafter are “released” into the blood,
the values of these two parameters may change even
divergently [24].
Also the following hypothesis to explain the apparent
inconsistency between our results and those of other
authors should be taken into consideration. It is known
that total body irradiation after
131I administration rises
with increasing whole-body retention time of radioisotope
[25]. As no dosimetric data are available for patients
studied by Konukoğlu et al., Bartoc et al., as well as
Wolfram et al., it can be speculated that lower thyroid
remnants
131I uptake and shorter whole-body retention
time of
131I in our patients resulted in lower irradiation of
tissues, and, as a consequence, lower LPO [18,23,24].
However, in the opinion of the authors of the present
study, such a mechanism does not play an essential role.
The negative correlation between radioiodine dose and
LPO level, observed in the present study early after
radioiodine treatment was not expected. However, this
relationship may be explained by well documented pro-
tective effects of ionizing radiation used in compara-
tively low doses [17,26]. Low doses of ionizing radiation,
as well as low doses of any other prooxidant, stimulate
intracellular protective mechanisms, antioxidative
enzymes included [27]. It is worth stressing that in the
present study LPO level decreased slightly within the
first two days after radioiodine treatment and that this
decrease would be possibly statistically significant in
case of much lower baseline value (such as in the con-
trol group). Huge increase in LPO level due to severe
hypothyroidism made impossible to clearly reveal the
decrease in LPO level due to radioiodine treatment.
However, this hypothesis should be experimentally
proved, for example by measurement of other indices of
oxidative damage to macromolecules. Nevertheless, the
negative correlation between radioiodine dose and LPO
level early after radioiodine treatment intensifies the
main finding of the present study, showing that ablative
doses of
131I do not induce significant peroxidation of
membrane lipids in thyroid cancer patients within the
first days of therapy. This finding is of great clinical
importance and relates especially to those thyroid cancer
patients, who are not treated with recombinant TSH,
thus being hypothyroid not only before but also shortly
after radioiodine therapy.
Table 1 TSH concentration and LPO level (expressed as MDA + 4-HDA concentration) in the control group and
hypothyroid patients treated with
131I
TSH (mIU/l) MDA + 4-HDA (nmol/ml)
day “0” day “1” day “2” day “3” day “4”
Control patients 1.9 ± 0.5 4.9 ± 2.1
Hypothyroid patients 60.2 ± 28.7 24.9 ± 12.7 22.2 ± 8.9 23.1 ± 10.0 23.9 ± 9.8 25.2 ± 8.0
All data represent mean ± SD.
Table 2 Correlations between administered activity of
131I
and LPO level in thyroid cancer patients. rs - correlation
coefficient
Day No “1”“ 2”“ 3”“ 4”
rs value rs = -0.42 rs = -0.57 rs = -0.09 rs = -0.15
p value p = 0.06 p = 0.006 p = 0.7 p = 0.54
Value being statistically significant is marked in bold.
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differentiated thyroid cancer does not further increase
oxidative damage to membrane lipids, at least early, i.e.
within the first 4 days, after therapy.
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